Palomar Medical Expands Its Product Portfolio Through a Distribution Agreement with Astron Clinica
23 7월 2008 - 9:00PM
PR Newswire (US)
BURLINGTON, Mass., July 23 /PRNewswire-FirstCall/ -- Palomar
Medical Technologies, Inc. (NASDAQ:PMTI), a leading researcher and
developer of light-based systems for cosmetic treatments, announced
today that it has entered into a Distribution Agreement with Astron
Clinica, Ltd. to distribute a range of aesthetic imaging products
in the United States and Canada. The agreement gives Palomar
exclusive distribution rights to sell Beau Visage(TM), a clinically
proven skin imaging and consultation system, to medical
professionals. Palomar's customers can use Beau Visage(TM) during
initial client meetings to visualize and measure blood, pigment,
and wrinkles before recommending the most effective cosmetic
treatments available using Palomar's StarLux(TM) Laser and Pulsed
Light System. Palomar's customers can use Beau Visage during
subsequent visits to show changes in their clients' skin by
tracking and measuring actual improvement in skin appearance.
Providing such quantifiable data on changes in skin health should
greatly improve client satisfaction. Customers using Beau Visage in
conjunction with Palomar products are able to better tailor
treatments to the specific needs of each client and then
demonstrate and quantify the before-and-after effect of Palomar
treatments. This should enable Palomar customers to sell more
treatments, thereby increasing revenue and decreasing time to
return on investment in Palomar aesthetic light based systems. Also
under the Distribution Agreement, Palomar will sell Astron
Clinica's Physiometrics(TM) photographic imaging system which
captures a library of images of the body. This new technology will
allow for visual documentation of the benefits that will be seen
using the recently introduced Palomar Aspire(TM) SlimLipo(TM)
laser-assisted lipolysis system. Commenting on this agreement
Joseph P. Caruso, Chief Executive Officer of Palomar, said,
"Working with Astron Clinica enables Palomar to sell additional
products to its customers that help them increase revenues and
improve client satisfaction. Our customers will be able to use
Astron Clinica products to sell more aesthetic procedures, which
are better tailored to the needs of each specific client, and show
clients their actual improvement." Prof. Annie Brooking, CEO of
Astron Clinica, said, "We are delighted with this relationship with
Palomar, the industry leader in light-based aesthetic products. The
products of Palomar and Astron Clinica are truly synergistic and
enable both companies to deliver a superior service to our
customers." About Palomar Medical Technologies, Inc.: Palomar is a
leading researcher and developer of light-based systems for
cosmetic treatments. Palomar pioneered the optical hair removal
field, when, in 1997, it introduced the first high-powered laser
hair removal system. Since then, many of the major advances in
light-based hair removal have been based on Palomar technology. In
December 2006, Palomar became the first company to receive a 510(k)
over-the-counter (OTC) clearance from the United States Food and
Drug Administration (FDA) for a new, patented, home use,
light-based hair removal device. OTC clearance allows the product
to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic
procedures performed around the world every year in physician
offices, clinics, spas and salons. Palomar is testing many new and
exciting applications to further advance the hair removal market
and other cosmetic applications. Palomar is focused on developing
proprietary light-based technology for introduction to the mass
markets. Palomar has granted The Procter & Gamble Company a
non-exclusive License Agreement to certain patents, technology and
FDA documents related to the home-use, light-based hair removal
field for women. In addition, Palomar has an exclusive development
and license agreement with Johnson & Johnson Consumer Companies
to develop and potentially commercialize home-use, light-based
devices for reducing or reshaping body fat including cellulite,
reducing the appearance of skin aging, and reducing or preventing
acne. About Astron Clinica, Ltd.: Astron Clinica is a global skin
imaging company, based in Cambridge UK and with offices in New York
and Brisbane. Astron Clinica designs, develops and brings to market
skin imaging products that incorporate its proprietary skin imaging
technology SIAscopy(TM). SIAscopy(TM) uniquely enables medical,
pharmaceutical, cosmetic and aesthetic industry professionals to
visualize up to 2mm beneath the surface of the skin using both a
proprietary hand held scanner and an off-the-shelf digital camera.
Awarded Frost & Sullivan's 2006 European Technology Innovation
of the Year Award, Astron Clinica's products use SIAscopy(TM) to
allow the measurement and non-invasive visualization of the major
dermatological constituents of skin -- blood, pigment and collagen
-- in vivo for the first time. SIAscopy(TM) is a technology that is
trusted globally to help diagnose skin conditions as severe as skin
cancer. Astron Clinica's customers include dermatologists, plastic
surgeons, hospitals, GPs, beauty clinics and aesthetic medicine
practitioners. This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
on the Company's current expectations, plans, intentions, beliefs
or predictions. These forward-looking statements are neither
promises nor guarantees, but involve risk and uncertainties that
may individually or mutually impact the matters herein, and cause
actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but
are not limited to, results of future operations, technological
difficulties in developing or introducing new products, the results
of future research, lack of product demand and market acceptance
for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third
parties and government contracts, the impact of competitive
products and pricing, governmental regulations with respect to
medical devices, including whether FDA clearance will be obtained
for future products and additional applications, the results of
litigation, including patent infringement lawsuits, difficulties in
collecting royalties, potential infringement of third-party
intellectual property rights, factors affecting the Company's
future income and resulting ability to utilize its NOLs, and/or
other factors, which are detailed from time to time in the
Company's SEC reports, including the report on Form 10-K for the
year ended December 31, 2007 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. The Company undertakes no obligation to release publicly
the result of any revisions to these forward-looking statements
that may be made to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
Contacts: Kayla Castle Prof. Annie Brooking Investor Relations
Manager Chief Executive Officer Palomar Medical Technologies, Inc.
Astron Clinica, Ltd. 781-993-2411 +44 1223 265000 DATASOURCE:
Palomar Medical Technologies, Inc. CONTACT: Kayla Castle, Investor
Relations Manager of Palomar Medical Technologies, Inc.,
+1-781-993-2411, ; or Prof. Annie Brooking, Chief Executive Officer
of Astron Clinica, Ltd., +44-1223-265000 Web site:
http://www.palmed.com/ Company News On-Call:
http://www.prnewswire.com/comp/107555.html
Copyright
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024